BAY 57-1293

BAY 57-1293 is a potent helicase primase inhibitor. It inhibits replication of herpes simplex virus (HSV) type 1 and type 2 in the nanomolar range in vitro by abrogating the enzymatic activity of the viral primase-helicase complex. In various rodent models of HSV infection the antiviral activity of BAY 57-1293 in vivo was found to be superior compared to all compounds currently used to treat HSV infections. BAY 57-1293 has been shown to be a more effective agent than acyclovir (Cat. No. 2200) for treating Alzjeimer’s Disease (AD) by decreasing Aβ and P-tau formation.